Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER					PATIENT:			
Name	:				Name:			
Ward:					NHI:			
Posaconazole								
INITIATION Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate)								
and	Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that endorsed by the Health NZ Hospital.							
	and (or O	O Patient has acute myeloid leukaemia O Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection Patient is to be treated with high dose remission induction therapy or re-induction therapy					
CONTINUATION Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.								
	and	C	Patie	nt has previously received posaconazole prophylaxis duri	ng remission induction therapy			
		or or	O O O	Patient is to be treated with high dose remission re-induced Patient is to be treated with high dose consolidation there Patient is receiving a high risk stem cell transplant				

0:	D - 1 - 1	
Zigneg.	i jate:	
Oigilica.	 Duic.	